Approval · Notice of Compliance 37418 · 2026
MENQUADFI: Notice of Compliance 37418
Issued March 26, 2026
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 37418
- Date
- March 26, 2026
- Company
- Sanofi Pasteur LimitedSwiftwater, Pennsylvania, United States
- Product type
- Biologic
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Expansion of the indication: MenQuadfi (Meningococcal (Groups A, C, Y, W) Polysaccharide Tetanus Toxoid Conjugate Vaccine) is indicated for the prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, W and Y in individuals 6 weeks of age and older. MenQuadfi does not prevent N. meningitidis serogroup B disease.
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| MENQUADFI | Not yet assigned | — |
Medicinal ingredients
- MENINGOCOCCAL GROUP A POLYSACCHARIDE-TETANUS TOXOID CONJUGATE 10 MCG per 0.5ML
- MENINGOCOCCAL GROUP C POLYSACCHARIDE-TETANUS TOXOID CONJUGATE 10 MCG per 0.5ML
- MENINGOCOCCAL GROUP W POLYSACCHARIDE-TETANUS TOXOID CONJUGATE 10 MCG per 0.5ML
- MENINGOCOCCAL GROUP Y POLYSACCHARIDE-TETANUS TOXOID CONJUGATE 10 MCG per 0.5ML